March is MS Awareness Month, which means it’s time for the usual mix of orange ribbons, inspirational stories, and well-meaning but kinda empty “We see you!” messages. Don’t get me wrong—I appreciate the awareness. But you know what would really make me feel seen? A drug that actually repairs the damage MS has done to my brain and spine.
That’s why I’ve been watching PIPE-307 so closely. A remyelination drug. Not just symptom management. Not just slowing progression. Actual repair. That’s the dream, right? And for the first time, it feels like it might be within reach. The trials have been promising and Phase II trial resultes are expected in the third quarter. Johnson & Johnson even jumped in, which tells me there’s real potential here.
But right when something exciting could be happening, here comes the gut punch—cuts to the FDA. Less oversight, fewer resources, and a slower, messier approval process. And yeah, bureaucracy isn’t fun, but you know what’s worse? A drug that works but never makes it to market because the system is too broken to move it forward.
So as MS Awareness Month starts, I’m stuck wondering—what’s the better outcome? PIPE-307 just straight-up failing so I don’t get my hopes up again? Or it actually working and then getting buried in regulatory limbo?
Love that for us.
MS Awareness Month is supposed to be about hope. About pushing for better treatments, better support, better lives for people with MS. But awareness means nothing if we don’t have the systems in place to make real progress happen.
wheels & red 